Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast...
Demetria Smith-Graziani, MD,...